Editas Medicine, Inc.

DB:8EM Stock Report

Market Cap: €357.9m

Editas Medicine Valuation

Is 8EM undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

1/6

Valuation Score 1/6

  • Below Future Cash Flow Value

  • Significantly Below Future Cash Flow Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 8EM when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Ultimate guide to DCF valuation for stock investing

Learn how to determine fair value like the best investors in the world.

Below Future Cash Flow Value: Insufficient data to calculate 8EM's future cash flow value for valuation analysis.

Significantly Below Future Cash Flow Value: Insufficient data to calculate 8EM's future cash flow value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 8EM?

Key metric: As 8EM is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for 8EM. This is calculated by dividing 8EM's market cap by their current revenue.
What is 8EM's PS Ratio?
PS Ratio10.2x
SalesUS$38.69m
Market CapUS$412.81m

Price to Sales Ratio vs Peers

How does 8EM's PS Ratio compare to its peers?

The above table shows the PS ratio for 8EM vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average13.5x
FYB Formycon
6.5x26.71%€339.0m
BIO0 Biotest GmbH KGaA
2xn/a€1.3b
LQ0 Dextech Medical
43.6xn/a€198.7m
BIO3 Biotest
1.8xn/a€1.4b
8EM Editas Medicine
10.2x-24.05%€412.8m

Price-To-Sales vs Peers: 8EM is good value based on its Price-To-Sales Ratio (10.2x) compared to the peer average (11.2x).

Historical Price to Sales Ratio

Historical Price to Sales Ratio compares a stock's price to its sales over time. Higher ratios indicate that investors are willing to pay more for the stock.

Fetching historical data

Price to Sales Ratio vs Industry

How does 8EM's PS Ratio compare vs other companies in the DE Biotechs Industry?

14 CompaniesPrice / SalesEstimated GrowthMarket Cap
BIO3 Biotest
1.8xn/aUS$1.63b
BIO0 Biotest GmbH KGaA
2xn/aUS$1.51b
7V0 Novogenia
1.5x26.52%US$92.74m
2INV 2invest
2.2xn/aUS$72.38m
8EM 10.2xIndustry Avg. 9.3xNo. of Companies14PS01224364860+
14 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Sales vs Industry: 8EM is expensive based on its Price-To-Sales Ratio (10.2x) compared to the European Biotechs industry average (8.6x).

Price to Sales Ratio vs Fair Ratio

What is 8EM's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

8EM PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio10.2x
Fair PS Ratio0.05x

Price-To-Sales vs Fair Ratio: 8EM is expensive based on its Price-To-Sales Ratio (10.2x) compared to the estimated Fair Price-To-Sales Ratio (0.1x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst 8EM forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Current€2.32
€4.97
+114.18%
64.13%€12.90€0.86n/a9
Jul ’27€2.88
€4.97
+72.53%
64.13%€12.90€0.86n/a9
Jun ’27€2.92
€4.97
+70.17%
64.13%€12.90€0.86n/a9
May ’27€2.38
€4.88
+104.99%
65.27%€12.79€0.85n/a9
Apr ’27€2.08
€4.75
+128.52%
58.13%€11.22€0.86n/a9
Mar ’27€1.77
€4.30
+142.87%
62.82%€10.78€0.83n/a8
Feb ’27€1.66
€4.30
+158.64%
62.82%€10.78€0.83n/a8
Jan ’27€1.73
€4.29
+147.71%
63.68%€11.28€0.87n/a9
Dec ’26€1.87
€4.29
+129.49%
63.68%€11.28€0.87n/a9
Nov ’26€2.62
€3.41
+30.12%
37.80%€5.12€0.85n/a7
Oct ’26€3.00
€3.41
+13.81%
37.80%€5.12€0.85n/a7
Sep ’26€2.15
€3.31
+53.96%
37.48%€5.13€0.85n/a8
Aug ’26€2.10
€2.87
+36.96%
32.92%€4.26€0.85€2.328
Jul ’26€1.80
€2.94
+63.26%
32.92%€4.35€0.87€2.888
Jun ’26€1.56
€3.03
+93.67%
32.92%€4.48€0.90€2.928
May ’26€1.30
€3.50
+168.60%
48.41%€7.00€0.88€2.388
Apr ’26€1.08
€3.43
+217.92%
57.73%€7.32€0.92€2.088
Mar ’26€1.83
€3.64
+98.32%
57.73%€7.76€0.97€1.778
Feb ’26€1.30
€3.64
+178.99%
57.73%€7.76€0.97€1.668
Jan ’26€1.19
€3.49
+194.45%
56.04%€7.62€0.95€1.739
Dec ’25€2.07
€7.71
+273.14%
46.60%€14.18€0.94€1.8713
Nov ’25€2.53
€10.78
+326.66%
43.85%€21.32€2.78€2.6216
Oct ’25€3.00
€12.15
+304.86%
44.37%€24.29€6.30€3.0016
Sep ’25€3.22
€12.40
+284.82%
45.70%€24.73€6.41€2.1515
Aug ’25€4.89
€13.19
+169.59%
42.86%€24.96€6.47€2.1015
€5.2
Fair Value
55.3% undervalued intrinsic discount
9
Number of Analysts

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/07/31 08:54
End of Day Share Price 2026/07/31 00:00
Earnings2026/03/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Editas Medicine, Inc. is covered by 24 analysts. 11 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Jack AllenBaird
Joel BeattyBaird
Alec StranahanBofA Global Research